Bestopmed Scores Millions of Yuan in Angel Round of Financing

(VCBeat) May. 7, 2021 -- Tianjin Bestopmed Co., Ltd. ("Bestopmed") recently announced that it has completed a multi-million-yuan angel round of financing in January 2021, with exclusive participation from Shanghai Qingfeng Capital. The proceeds will enable Bestopmed to complete the construction of the single-cell diagnostic instrument and reagents transformation platform, and the technical analysis system.

Bestopmed was founded by a senior team of scientists of high-throughput single-cell sequencing technology. It is committed to building China's advanced tumor cell diagnostic brand, providing a full range of solutions covering single-cell analysis instruments, reagents, medical diagnosis technology analysis and so on, to make individualized diagnosis and treatment of tumors more efficient.

In the field of biomedical detection, the continuous improvement of detection accuracy is the general trend. Compared with previous detection techniques, single-cell sequencing technology is substantially improved in describing differences at the cell level. It can provide unprecedented resolution and precision in the aspects of cell clone recognition, difference presentation and cell population description, etc., and is especially suitable for the detection of heterogeneity of tumor cells and immune system diversity, etc.

Headquartered in Binhai New Area, Tianjin, Bestopmed has an R&D service center in Beijing. The management team and technical team of Biao Pharma have rich experience in single-cell analysis and R&D. They have successfully built the earliest and most experienced single-cell research and service team in China, and have in-depth cooperation with international leading platform companies such as 10X Genomics, BD, Mission Bio, etc. The company has a deep understanding of single-cell sequencing technology, products and applications.

Shanghai Qingfeng Capital was founded jointly by a number of senior executives of listed companies. The early partners are the returnees, executives of listed companies, angel investors, and other experts in multiple fields. The company is committed to investing in medicine and health, intelligent manufacturing, new energy and other industries concerning science and technology.